315 related articles for article (PubMed ID: 11576213)
1. Immunotherapy of melanoma.
Smith C; Cerundolo V
Immunology; 2001 Sep; 104(1):1-7. PubMed ID: 11576213
[No Abstract] [Full Text] [Related]
2. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
3. Melanoma vaccines.
Perales MA; Wolchok JD
Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
[TBL] [Abstract][Full Text] [Related]
4. The unfulfilled promise of melanoma vaccines.
Livingston P
Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
[No Abstract] [Full Text] [Related]
5. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
6. Melanoma vaccines: breakthrough or bust?
Sabel MS; Sondak VK
Cancer Invest; 2002; 20(7-8):1114-6. PubMed ID: 12449744
[No Abstract] [Full Text] [Related]
7. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD; Snyder A
Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
9. Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
Lejeune FJ
Melanoma Res; 2006 Oct; 16(5):377-8. PubMed ID: 17013085
[No Abstract] [Full Text] [Related]
10. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; LiƩnard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
11. Skin cancer--prospects for novel therapeutic approaches.
Stingl G
Ernst Schering Res Found Workshop; 2000; (30):137-53. PubMed ID: 10943321
[No Abstract] [Full Text] [Related]
12. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
13. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
14. Cancer immunotherapy. Neo approaches to cancer vaccines.
Delamarre L; Mellman I; Yadav M
Science; 2015 May; 348(6236):760-1. PubMed ID: 25977539
[No Abstract] [Full Text] [Related]
15. Evaluation of immunotherapy in the treatment of melanoma.
Faries MB
Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
17. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
Marincola FM; Ferrone S
Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
[No Abstract] [Full Text] [Related]
18. Dendritic cells in melanoma immunotherapy.
Faries MB; Czerniecki BJ
Curr Treat Options Oncol; 2005 May; 6(3):175-84. PubMed ID: 15869729
[TBL] [Abstract][Full Text] [Related]
19. Special report: vaccines for the treatment of malignant melanoma.
Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143
[TBL] [Abstract][Full Text] [Related]
20. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]